Oxidative stress in Parkinson's disease

Neuropathology and Applied Neurobiology

Volumn 21, Issue 1, 1995, Pages 3-9

  Schapira, A H V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

free radicals; iron; L Dopa; mitochondria; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; FREE RADICAL; IRON; NEUROMELANIN; NEUROTOXIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

CELL DEATH; DOPAMINERGIC NERVE CELL; HEREDITY; HUMAN; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NERVE CELL NECROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW;

ANIMAL; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0028924168     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.1995.tb01022.x     Document Type: Review

References (72)

1. Brain peroxidase and catalase in Parkinson's disease
2. Mutant debrisoquine hydroxylation genes in Parkinson's disease
3. Sequential damage in mitochondrial complexes by peroxidase stress
4. Brain dopamine and the syndromes of Parkinson and Huntington
5. Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine
6. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by MPTP
7. The free radical hypothesis in idiopathic parkinsonism: evidence against it
8. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease
9. Irreversible inhibition of mitochondrial complex I by 1‐methyl‐4‐phenylpyridinium: evidence for free radical involvement
10. Increased nigral iron content in post‐mortem parkinsonian brain
11. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
12. Decreased ferritin levels in brain in Parkinson's disease
13. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia
14. α‐Tocopherol levels in brain are not altered in Parkinson's disease
15. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients
16. Free radicals, lipid peroxidation and l‐methyl‐4‐phenyl‐l,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism
17. 3H]dihydrorotenone
18. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it
19. Ageing and Parkinson's disease: substantia nigra regional selectivity
20. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra and differential cell death in Parkinson's disease
21. A large kindred with autosomal dominant Parkinson's disease
22. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
23. N‐methylation of pyridines in Parkinson's disease
24. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease
25. 1‐methyl‐4‐phenylpyridiniurn (MPP+) induces NADH dependent superoxide formation, and enhances NADH‐dependent lipid peroxidation in bovine heart submitochon‐drial particles
26. Long‐term administration of L‐dopa does not damage dopaminergic neurons in the mouse
27. Repiratory activity of isolated rat brain mitochondria following in vitro exposure to oxygen radicals
28. Melanised dopaminergic neurones are differentially susceptible to degeneration in Parkinson's disease
29. Parkinsonism‐inducing MPTP: uptake of the metabolite MPP+ by dopamine neurones explains selective toxicity
30. Oxidative stress as a cause of Parkinson's disease
31. Twin studies and the genetics of Parkinson's disease — a reappraisal
32. Glutathione peroxidase activity in Parkinson's disease
33. Chronic parkinsonism in humans due to a product of meperidine analog synthesis
34. When did Ray Kennedy's Parkinson's disease begin
35. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect
36. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease
37. Quantitation of a mitochondrial DNA deletion in Parkinson's disease
38. Complex I, iron and ferritin in Parkinson's disease substantia nigra
39. A clinical and genetic study of familial Parkinson's disease
40. Evidence to support early use of l‐dopa therapy in Parkinson's disease
41. Rate of cell death in parkinsonism indicates active neuropathological process
42. Neurotoxicity of levodopa on catecholamine‐rich neurons
43. Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
44. Alteration of inner‐membrane components and damage to electron‐transfer activities of bovine heart submitochondrial particles induced by NADPH‐dependent lipid peroxidation
45. Inhibition of NADH‐linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP
46. Ascorbic acid protects against l‐dopa induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line
47. Parkinson's disease: a disorder due to nigral glutathione deficiency
48. Nigrostriatal dopamine neurons remain undamaged in rats given high doses of L‐dopa and carbidopa chronically
49. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients
50. Transgenic mice with increased Cu/Zn‐superoxide dismutase activity are resistant to N‐methyl‐4‐phenyl 1,2,3,6 tetrahydropyridine‐induced neurotoxicity
51. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity
52. Early onset Parkinson's disease and childhood environment
53. Energy driven uptake of MPP+ by brain mitchondria mediates the neurotoxicity of MPTP
54. Interaction of MPP and its analogs with the rotenonelpiericidin binding site of NADH dehydrogenase
55. Transition metals, ferritin. glutathione and ascorbic acid in parkinsonian brains
56. A selective increase in particulate superoxide dismutase activity in Parkinson's suhstantia nigra
57. Oxidation of the neurotoxic amine MPTP by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP
58. Evidence for mitochondrial dysfunction in Parkinson's disease: a critical appraisal
59. Mitochondrial complex I deficiency in Parkinson's disease
60. Mitochondrial complex I deficiency in Parkinson's disease
61. 1 reductase (complex I) deficiency in Parkinson's disease
62. Mitochondrial DNA analysis in Parkinson's disease
63. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
64. Selective increase of iron in substantia nigra zona compacta in parkinsonian brains
65. Xenohiotic metabolism in Parkinson's disease
66. NADH‐ and NADPH‐dependent formation of superoxide anions by bovine heart submitochondrial particles
67. Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function
68. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration
69. The possible role of iron in the etiopathology of Parkinson's disease
70. The oxidative inactivation of mitochondrial electron transport chain components and ATP